Ads
related to: exogenous surfactant therapy for depression mayo clinic
Search results
Results from the WOW.Com Content Network
Newer MAOIs such as selegiline (typically used in the treatment of Parkinson's disease) and the reversible MAOI moclobemide provide a safer alternative [19] and are now sometimes used as first-line therapy. Pargyline is a non-selective MAOI that was previously used as an antihypertensive agent to treat hypertension (high blood pressure). [21] [22]
Surfactant therapy is the medical administration of pulmonary surfactant that is derived from outside of the body. Pulmonary surfactant is a soap-like chemical synthesized by type II alveolar pneumocytes and is of various lipids (80% phospholipids, 5-10% cholesterol, and ∼10% surfactant-associated proteins).
Management of depression is the treatment of depression that may involve a number of different therapies: medications, behavior therapy, psychotherapy, and medical devices. Depression is a symptom of some physical diseases; a side effect of some drugs and medical treatments; and a symptom of some mood disorders such as major depressive disorder ...
Endogenous depression is an atypical subclass of major depressive disorder (clinical depression). It could be caused by genetic and biological factors. [ 1 ] Endogenous depression occurs due to the presence of an internal (cognitive, biological) stressor instead of an external (social, environmental) stressor. [ 2 ]
As Americans are increasingly reaching for pharmaceutical solutions for depression—about one in eight U.S. adults takes antidepressants—scientists have been innovating novel treatments for it.
The biology of depression is the attempt to identify a biochemical origin of depression, as opposed to theories that emphasize psychological or situational causes. Scientific studies have found that different brain areas show altered activity in humans with major depressive disorder (MDD) . [ 1 ]
Ads
related to: exogenous surfactant therapy for depression mayo clinic